Current Report Filing (8-k)
25 Août 2022 - 07:33PM
Edgar (US Regulatory)
0001065078
false
0001065078
2022-08-24
2022-08-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported): August
24, 2022
Network-1 Technologies, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
001-15288 |
11-3027591 |
(State or Other Jurisdiction |
(Commission |
(I.R.S. Employer |
of Incorporation) |
File Number) |
Identification No.) |
65
Locust Avenue, Third Floor, New
Canaan, Connecticut 06840
(Address of Principal
Executive Offices) (Zip Code)
(203) 920-1055
(Registrant’s
telephone number, including area code)
N/A
(Former name or former address,
if changed since last report)
Securities registered
pursuant to Section 12(b) of the Act:
Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
Common
Stock, par value $0.01 per share
|
NTIP
|
NYSE American |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On August 24,
2022, ILiAD Biotechnologies LLC (“ILiAD”) completed a private financing of $42,836,000 of Class D units, of which a multi-national
pharmaceutical company invested $30,000,000 (the “Financing”). As part of the Financing, Network-1 Technologies, Inc. (the
“Company”) invested $1,000,000 and its convertible note in the principal amount of $1,000,000 plus accrued interest, in accordance
with its terms, converted into units of ILiAD. Since December 2018, the Company has invested an aggregate of approximately $7,000,000
in ILiAD. ILiAD is a clinical stage biotechnology company dedicated to the prevention and treatment of human disease caused by Bordetella
pertussis and is developing technologies that focus on validating its proprietary intranasal vaccine (BPZE1) for the prevention of pertussis
(whooping cough).
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
NETWORK-1 TECHNOLOGIES, INC. |
|
|
|
|
|
|
Dated August
25, 2022 |
By: |
/s/ Corey M.
Horowitz |
|
|
Name: Corey
M. Horowitz
Title: Chairman
& Chief Executive Officer
|
|
|
|
-3-
Network 1 Technologies (AMEX:NTIP)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Network 1 Technologies (AMEX:NTIP)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024